← Library
Pramlintide
FDA ApprovedSince 2005
Also known as Symlin
Function
Primary
Type 1 Diabetes · Type 2 Diabetes (adjunct to insulin)
Mechanism
Synthetic amylin analog — slows gastric emptying, suppresses postprandial glucagon, promotes satiety via CNS.
Evidence
Clinical RCT (Phase III)
Research
Phase III PRACTICAL trials
Dosing
Range
15–120 mcg before meals
Frequency
TID (with meals)
Route
Subcutaneous
Cycling
Continuous; requires insulin dose reduction.
Benefits
- ·Postprandial glucose control
- ·Modest weight loss
- ·Adjunct to insulin therapy
Risks
- ·Severe hypoglycemia with insulin (black box)
- ·Nausea
- ·Anorexia
Contraindications
- ·Gastroparesis
- ·Hypoglycemia unawareness
- ·HbA1c >9%
Regulatory
FDA-Approved Rx
Functional Groups
Cited Works
- AstraZeneca. SYMLIN (pramlintide) Prescribing Information.